EKF diagnostics

EKF Diagnostics Holdings plc specialises in the development, production and distribution of near patient analysers, clinical chemistry and DNA enrichment kits. Our range of blood analysers are simple to use and designed to quickly deliver accurate results to aid the diagnosis of anemia, diabetes and associated conditions. EKF analyzers are used in more than 70 countries by healthcare professionals in blood banks, GP surgeries, diabetes clinics, pharmacies, hospitals, sports medicine and laboratories. We are also a worldwide leader in the manufacture and distribution of organ injury biomarkers specialising in acute injury to kidneys (AKI), liver and pancreas. Our microtitre plate assay kits have particular application in assessing the safety and effectiveness of drug candidates in clinical trials. EKF Diagnostics recently acquired the UK-based technology company, 360 Genomics, gaining access to their gene detection technologies; PointManTM and CounterPoint™. 360 Genomics then went on to become EKF Molecular Diagnostics Ltd a subsidiary of EKF Diagnostics Holdings Plc. The EKF Molecular management team has a wealth of experience in the global field of molecular diagnostics. This was shortly followed by the acquisition of Selah Genomics Inc and DiaSpect Medical AB in early 2014 further adding to the diversity of EKF Diagnostics product portfolio. Today EKF Diagnostics has distributors in more than 100 locations around the globe, multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK and a board led by some of foremost authorities in medical diagnostics in the world.
Type
Public
HQ
Penarth, GB
Founded
1990
Size (employees)
365 (est)-7%
EKF diagnostics was founded in 1990 and is headquartered in Penarth, GB

EKF diagnostics Office Locations

EKF diagnostics has an office in Penarth
Penarth, GB (HQ)
Avon House 19 Stanwell Rd

EKF diagnostics Financials and Metrics

EKF diagnostics Financials

EKF diagnostics's revenue was reported to be £38.6 m in FY, 2016 which is a 28% increase from the previous period.
GBP

Revenue (FY, 2016)

38.6 m

Gross profit (FY, 2016)

18.3 m

Gross profit margin (FY, 2016), %

47%

Net income (FY, 2016)

169 k

EBITDA (FY, 2016)

946 k

EBIT (FY, 2016)

(327 k)

Market capitalization (31-Oct-2017)

116.1 m

Closing share price (31-Oct-2017)

0.2

Cash (31-Dec-2016)

7.9 m

EV

112.6 m
EKF diagnostics's current market capitalization is £116.1 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

1.9 m465 k256 k6.5 m21.7 m26.1 m31.8 m37.1 m30 m38.6 m

Revenue growth, %

17%(19%)

Cost of goods sold

1 m3.6 m11.3 m11.7 m15.5 m17.9 m15.4 m20.3 m

Gross profit

845 k2.9 m10.4 m14.3 m16.3 m19.2 m14.7 m18.3 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

1.4 m2.5 m3 m3.2 m5.3 m4.3 m2.6 m8.3 m2 m7.9 m

Accounts Receivable

380 k354 k3 k2 m4.3 m3.9 m4.8 m11.8 m4.1 m5.6 m

Inventories

110 k3 m4.8 m5 m5.3 m5.8 m8.2 m6 m

Current Assets

2.1 m3 m4.2 m9.9 m14.5 m13.2 m15.1 m30.3 m17.5 m23.3 m
    GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    465 k(1.1 m)(203 k)(2 m)(2.6 m)410 k(893 k)(4.9 m)(13.6 m)169 k

    Cash From Operating Activities

    584 k(647 k)(675 k)(1.4 m)(806 k)1.6 m2 m(4.7 m)(4.3 m)8.9 m

    Cash From Financing Activities

    (7 k)1.1 m11.9 m12.4 m(885 k)(1.6 m)26.4 m3.3 m(2.1 m)

    Net Change in Cash

    1.7 m1.1 m536 k125 k2 m(888 k)(1.8 m)5.8 m(6.3 m)5.4 m
      Y, 2016

      EV/EBITDA

      119 x

      EV/EBIT

      -344.2 x

      EV/CFO

      12.6 x

      Debt/Equity

      0.1 x

      Debt/Assets

      0.1 x

      Financial Leverage

      1.4 x
      Show all financial metrics

      EKF diagnostics Market Value History

      EKF diagnostics's Web-traffic and Trends

      EKF diagnostics Online and Social Media Presence

      EKF diagnostics Company Life and Culture

      You may also be interested in